Study Details
Testing Drug MTX-463 for Adults with Idiopathic Pulmonary Fibrosis
(IRB#: IRB_00191647)
Idiopathic Pulmonary Fibrosis is a condition that causes the lungs to scar and harden over time. This study will test a drug called MTX-463 to treat people with this disease. The study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen to receive MTX-463 or a placebo. A placebo looks like the study drug but does not have the medication. The drug and placebo are both given through a vein in the arm. Being in the study requires attending about 9 in-person visits to the study clinic over 32 weeks. Medical tests will be done during the study to track the health of participants. People will be paid for study participation.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 40 years and older
- Diagnosed with Idiopathic Pulmonary Fibrosis within 7 years of participation
- Participants being treated with pirfenidone or nintedanib must be on a stable dose for at least 90 days before participation
- Participants who stopped treatment with pirfenidone or nintedanib must have stopped at least 30 days before participation
- Childbearing age must use specific birth control
Exclusion Criteria
- Severe flare-up of Idiopathic Pulmonary Fibrosis at least 6 months before participation
- Requirement for receiving continuous supplemental oxygen. The use of intermittent supplemental oxygen, such as during exercise or sleep, is permitted.
- Expected to receive a lung transplant during the study
- Planned surgery during the study
- Currently smoking or vaping
Will I be paid for my time?
Yes
IRB#: IRB_00191647
PI: Mary Beth Scholand
Department: PULMONARY
Approval Date: 2025-12-10 07:00:00
Specialties: Pulmonary
I am Interested